Vericel vs Vir Biotechnology
Vericel is the larger business, with $276m of revenue in fiscal 2025 against $68.6m for Vir Biotechnology (4.0 times as much). Vericel grew faster (16.5% against -7.6%). Vericel kept more of each dollar of sales as profit: a net margin of 6.0% against -638.9%. Vericel carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | VericelVCEL, 2025 | Vir BiotechnologyVIR, 2025 |
|---|---|---|
| Revenue | $276m | $68.6m |
| Revenue growth | 16.5% | -7.6% |
| Net income | $16.5m | −$438m |
| Operating margin | 4.0% | -699.2% |
| Net margin | 6.0% | -638.9% |
| Return on equity | 5.1% | -45.7% |
| Free cash flow | $24.7m | −$397m |
| Cash | $100m | $232m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 398 | 367 |
| Market value | $2.10bn | $1.91bn |
| Price vs our value range | — | — |
| Moat score | 32 (Weak) | 27 (Weak) |
| Insider trades, 12 months | 0 buys, 33 sales | 0 buys, 35 sales |